The first CE-IVD approved test based on the TeaRx™ platform is intended for the identification and monitoring of Dry Eye Syndrome (TeaRx™ DES).
DES is a common disorder in which there is a decline in tear production or tear quality is impaired. Moderate and severe DES may cause pain and discomfort, and impair vision quality. In extreme cases, DES may even cause permanent blindness. Some 340 million people worldwide have DES, including some 40 million in the United States. Symptoms associated with DES account for about one third of patients’ complaints to ophthalmologists in the United States.
Despite its widespread prevalence, DES is complex and difficult to diagnose and treat since it may be caused by many underlying factors, resulting in diverse and distributed sub-populations suffering from the syndrome. Tear fluid is composed of a great many substances and a change in their concentration indicates a problem with the quality or volume of tears that causes the syndrome.
Multi-parameter analysis of the tear film proteins provides additional insights as per the etiology of the disease (e.g., evaporative, aqueous deficient, inflammatory DES) and may assist the ophthalmologist in prescribing the optimal treatment matched to the underlying cause of the disease. The clinical performance of the test was assessed in four clinical trials performed in the US and in Israel. Sensitivity and specificity levels exceeded 86% for detection of high severity DES.
TeaRx™ Dry Eye (3 parameters)
TeaRx™ Dry Eye
(3 parameters)
TeaRx™ Dry Eye (5 parameters)
TeaRx™ Dry Eye
(5 parameters)
In a large clinical trial (600 subjects):
Mr. Sinclair is a Canadian CPA with extensive experience in the field of finance, accounting and the audit of public companies. With a career spanning several decades, he has served as Senior Partner with various audit firms including Smith, Nixon LLP, Collins Barrow Toronto LLP and Baker Tilly WM LLP, including as Managing Partner of Baker Tilly WM LLP’s Toronto office. During these tenures, Sinclair played a pivotal role in initiating and driving growth, managing complex projects, and providing financial advisory services to clients around the world. Mr. Sinclair is currently a director of Lifeist Wellness Inc. (“Lifeist”), a company listed on the TSX Venture Exchange, where he also serves as the chair of the Lifeist audit committee. Mr. Sinclair graduated from the University of Toronto with a Bachelor of Arts, Commerce and Economics, in April 1983.
Igal Kohn is currently, and has been since January 2017, the CEO of Elcam. Mr. Kohn has been with Elcam for over 25 years, starting in January 1998 as the CFO. Mr. Kohn holds an Israeli CPA certification. As the CFO of Elcam, Mr. Kohn was responsible for overseeing all mergers and acquisitions activities, managing the Elcam’s subsidiaries and handling all financial and legal matters. Mr. Kohn’s extensive experience in financial management and strategic operations positioned him to lead Elcam as CEO.
Karin Gurevitz has served as BioLight Vice President, BioLight Group General Counsel and Company Secretary since 2015. Ms. Gurevitz is a veteran legal advisor with 25 years of experience in legal and compliance management in global public and private companies in various fields. Ms. Gurevitz holds an LL.B. and an MBA from Tel Aviv University, Israel and is a member of the Israel Bar Association.
Julia Reznick Zilberman has been serving as VP of Business Development at Psifas (National Initiative for Precision Medicine) since May 2024. Before joining Psifas, Ms. Reznick Zilberman led strategic initiatives 96 at a company developing AI solutions for drug development (January 2023 to February 2024) and served as VP of Finance (CFO) and Business Development at an innovative ophthalmology startup (January 2018 to January 2023), which successfully completed several funding rounds. Prior to that, Ms. Reznick worked for 18 years at Teva Pharmaceutical Industries, where she held various senior finance and commercial roles, including managing financial strategy and operations. Ms. Reznick Zilberman also consults for startup companies, providing her expertise in business development and financial strategy. Ms. Reznick Zilberman holds an MBA in Finance and Information Systems, as well as a bachelor’s degree in Economics and Management, both from Tel Aviv University.
Yaacov Michlin has served as CEO of Biolight since April 2020. Before joining Biolight, Mr. Michlin managed a medical device company selling mainly in U.S. and led such company’s initial public offering on the NASDAQ. Mr. Michlin currently serves on various boards of directors in the portfolio of Biolight and is leading the life sciences activities in IATI (umbrella organization of the Israeli high-tech sector). Mr. Michlin is also the chairman of MIXIII Health Tech IL, a major conference in Israel. Mr. Michlin has an MBA from the Technion, cum laude, LLM and LLB and BSC in Economics, cum laude, Bar Ilan University.
